Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06154538 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 170 participants, started 2023-11-01 and due to reach its primary completion in 2026-11-01. Interventions recorded: Immune checkpoint inhibitor; FOLFOX regimen. Conditions listed: Locally Advanced Colorectal Carcinoma. Primary outcome: pCR rate. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colorectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.